Anat Ben-Shlomo

Summary

Affiliation: Cedars-Sinai Medical Center
Country: USA

Publications

  1. ncbi request reprint Cell-specific pituitary gene expression profiles after treatment with leukemia inhibitory factor reveal novel modulators for proopiomelanocortin expression
    Rula A Abbud
    Division of Endocrinology, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Endocrinology 145:867-80. 2004
  2. pmc Anti-aging therapy with human growth hormone associated with metastatic colon cancer in a patient with Crohn's colitis
    Gil Y Melmed
    Department of Medicine, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles, California 90048, USA
    Clin Gastroenterol Hepatol 6:360-3. 2008
  3. doi request reprint Pituitary gland: predictors of acromegaly-associated mortality
    Anat Ben-Shlomo
    Pituitary Center, Division of Endocrinology, Diabetes and Metabolism, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Davis Building, Room 3066, Los Angeles, CA 90048, USA
    Nat Rev Endocrinol 6:67-9. 2010
  4. pmc Acromegaly
    Anat Ben-Shlomo
    Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA, 90048, USA
    Endocrinol Metab Clin North Am 37:101-22, viii. 2008
  5. pmc Clusterin and FOXL2 act concordantly to regulate pituitary gonadotroph adenoma growth
    Vera Chesnokova
    Pituitary Center, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Mol Endocrinol 26:2092-103. 2012
  6. doi request reprint Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy
    Anat Ben-Shlomo
    Department of Medicine, Pituitary Center, Cedars SinaiMedical Center, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 94:4342-50. 2009
  7. pmc Lineage-specific restraint of pituitary gonadotroph cell adenoma growth
    Vera Chesnokova
    Department of Medicine, Pituitary Center, Cedars Sinai Medical Center, Los Angeles, California, United States of America
    PLoS ONE 6:e17924. 2011
  8. pmc Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth
    Vera Chesnokova
    Department of Medicine, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90048, USA
    Cancer Res 67:10564-72. 2007
  9. ncbi request reprint Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion
    Anat Ben-Shlomo
    Department of Medicine, Cedars Sinai Research Institute, David Geffen School of Medicine, UCLA, Los Angeles, California 90048, USA
    J Biol Chem 280:24011-21. 2005
  10. pmc Constitutive somatostatin receptor subtype 2 activity attenuates GH synthesis
    Anat Ben-Shlomo
    The Pituitary Center, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Endocrinology 154:2399-409. 2013

Collaborators

Detail Information

Publications86

  1. ncbi request reprint Cell-specific pituitary gene expression profiles after treatment with leukemia inhibitory factor reveal novel modulators for proopiomelanocortin expression
    Rula A Abbud
    Division of Endocrinology, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Endocrinology 145:867-80. 2004
    ..Thus, using GeneChips, C/EBPbeta and GIF have been identified as novel mediators and AHSG/fetuin as an inhibitor of LIF action in corticotropes...
  2. pmc Anti-aging therapy with human growth hormone associated with metastatic colon cancer in a patient with Crohn's colitis
    Gil Y Melmed
    Department of Medicine, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles, California 90048, USA
    Clin Gastroenterol Hepatol 6:360-3. 2008
    ..The nonapproved use of human growth hormone (HGH) for anti-aging has been increasing. Theoretical concerns for neoplastic potentiation by HGH have been raised, but not proven clinically...
  3. doi request reprint Pituitary gland: predictors of acromegaly-associated mortality
    Anat Ben-Shlomo
    Pituitary Center, Division of Endocrinology, Diabetes and Metabolism, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Davis Building, Room 3066, Los Angeles, CA 90048, USA
    Nat Rev Endocrinol 6:67-9. 2010
    ..A new study by Sherlock et al. now adds adrenal insufficiency and hydrocortisone replacement dose to the list of independent predictors of acromegaly-associated mortality...
  4. pmc Acromegaly
    Anat Ben-Shlomo
    Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA, 90048, USA
    Endocrinol Metab Clin North Am 37:101-22, viii. 2008
    ..Pharmacologic treatments, including long-acting somatostatin analogs, dopamine agonists, and growth hormone receptor antagonists, have assumed more importance in achieving biochemical and symptomatic disease control...
  5. pmc Clusterin and FOXL2 act concordantly to regulate pituitary gonadotroph adenoma growth
    Vera Chesnokova
    Pituitary Center, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Mol Endocrinol 26:2092-103. 2012
    ..Thus, gonadotroph tumor cell proliferation is determined by the interplay between cell-specific FOXL2 with PTTG and Clu...
  6. doi request reprint Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy
    Anat Ben-Shlomo
    Department of Medicine, Pituitary Center, Cedars SinaiMedical Center, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 94:4342-50. 2009
    ..However, there is no direct evidence for this assumption, and moreover, the ligand effect on corticotroph SST2 is not known...
  7. pmc Lineage-specific restraint of pituitary gonadotroph cell adenoma growth
    Vera Chesnokova
    Department of Medicine, Pituitary Center, Cedars Sinai Medical Center, Los Angeles, California, United States of America
    PLoS ONE 6:e17924. 2011
    ..These results point to lineage-specific pathways restricting uncontrolled murine and human pituitary gonadotroph adenoma cell growth...
  8. pmc Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth
    Vera Chesnokova
    Department of Medicine, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90048, USA
    Cancer Res 67:10564-72. 2007
    ....
  9. ncbi request reprint Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion
    Anat Ben-Shlomo
    Department of Medicine, Cedars Sinai Research Institute, David Geffen School of Medicine, UCLA, Los Angeles, California 90048, USA
    J Biol Chem 280:24011-21. 2005
    ..This may explain superior somatostatin-28 potency and provides a rationale for somatostatin ligand design to treat ACTH-secreting pituitary tumors...
  10. pmc Constitutive somatostatin receptor subtype 2 activity attenuates GH synthesis
    Anat Ben-Shlomo
    The Pituitary Center, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Endocrinology 154:2399-409. 2013
    ..In conclusion, modestly increased SSTR2 expression constitutively decreases GH synthesis, an effect partially mediated by GH promoter histone deacetylation...
  11. pmc Somatostatin agonists for treatment of acromegaly
    Anat Ben-Shlomo
    Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Mol Cell Endocrinol 286:192-8. 2008
    ..Disease control is evaluated by biochemical markers, tumor shrinkage, and disease-symptom improvement balanced against drug-related side effects...
  12. pmc Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor
    Ning Ai Liu
    Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Proc Natl Acad Sci U S A 108:8414-9. 2011
    ..The results suggest that use of selective CDK inhibitors could effectively target corticotroph tumor growth and hormone secretion...
  13. doi request reprint Molecular mechanisms of pituitary adenoma senescence
    Vera Chesnokova
    Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Front Horm Res 38:7-14. 2010
    ..In this review we highlight an intrinsic predisposition of pituitary tumors to exhibit senescence-associated molecular pathways and show prospective mechanisms underlying the benign nature of these commonly encountered tumors...
  14. ncbi request reprint Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation
    Anat Ben-Shlomo
    Department of Medicine, Cedars Sinai Research Institute, David Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA
    Mol Endocrinol 21:2565-78. 2007
    ....
  15. pmc Growth hormone is a cellular senescence target in pituitary and nonpituitary cells
    Vera Chesnokova
    Pituitary Center, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048
    Proc Natl Acad Sci U S A 110:E3331-9. 2013
    ..Thus, the results show that GH is a direct p53 transcriptional target and fulfills criteria as a p53 target gene. Induced GH is a readily measurable cell marker for p53-mediated cellular senescence. ..
  16. pmc EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas
    Hidenori Fukuoka
    Pituitary Center, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Clin Invest 121:4712-21. 2011
    ..These results indicate that inhibiting EGFR signaling may be a novel strategy for treating Cushing disease...
  17. ncbi request reprint Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells
    Anat Ben-Shlomo
    Division of Endocrinology and Metabolism, Cedars Sinai Research Institute, University of California School of Medicine, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 88:858-63. 2003
    ..These observations indicate a role for LIF in loss of autocrine PRL suppression contributing to unrestrained prolactinomas PRL secretion. Moreover, PRL suppression by LIF may be mediated by gp130 and D2R interaction...
  18. pmc p21(Cip1) restrains pituitary tumor growth
    Vera Chesnokova
    Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Proc Natl Acad Sci U S A 105:17498-503. 2008
    ..Aneuploid pituitary cell p21 may constrain pituitary tumor growth, thus accounting for the very low incidence of pituitary carcinomas...
  19. pmc Constitutive somatostatin receptor activity determines tonic pituitary cell response
    Anat Ben-Shlomo
    Cedars Sinai Medical Center, 8700 Beverly Boulevard, Academic Affairs, Room 2015, Los Angeles, California 90048, USA
    Mol Endocrinol 23:337-48. 2009
    ..Thus, integrated pituitary cell ACTH regulation is determined both by phasic SRIF action, as well as by tonic constitutive SST activity, independently of SRIF...
  20. ncbi request reprint Pasireotide--a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease
    Anat Ben-Shlomo
    Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    IDrugs 10:885-95. 2007
    ..The efficacy of pasireotide and any potential advantage over current therapies will need to be tested or validated in larger phase III clinical trials...
  21. ncbi request reprint Clinical review 154: The role of pharmacotherapy in perioperative management of patients with acromegaly
    Anat Ben-Shlomo
    Cedars Sinai Research Institute, University of California Los Angeles School of Medicine, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 88:963-8. 2003
  22. doi request reprint Lipodystrophy in patients with acromegaly receiving pegvisomant
    Vivien S Bonert
    Department of Medicine, Cedars Sinai Medical Center, David Geffen School of Medicine at University of California, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 93:3515-8. 2008
    ..Documented side effects in the initial registration studies included headache, injection-site reactions, flu-like syndrome, and reversible elevation of hepatic enzymes...
  23. pmc Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands
    George Vlotides
    Department of Medicine, Cedars Sinai Medical Center, University of California School of Medicine, Los Angeles, California 90048, USA
    Cancer Res 68:6377-86. 2008
    ..EGFR inhibitors could therefore be useful for the control of PRL secretion and tumor load in prolactinomas resistant to dopaminergic treatment, or for those prolactinomas undergoing rare malignant transformation...
  24. ncbi request reprint Murine pituitary tumor-transforming gene functions as a securin protein in insulin-secreting cells
    Run Yu
    UCLA School of Medicine, Cedars Sinai Research Institute, Cedars Sinai Medical Center, 8700 Beverly Blvd, Room D3066, Los Angeles, California 90048, USA
    J Endocrinol 191:45-53. 2006
    ....
  25. ncbi request reprint Medical progress: Acromegaly
    Shlomo Melmed
    Department of Medicine, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles 90048, USA
    N Engl J Med 355:2558-73. 2006
  26. pmc Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension
    Shlomo Melmed
    Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Pituitary 13:18-28. 2010
    ..Treatment was well tolerated by all patients. In conclusion, Lan-Autogel was effective in controlling GH and IGF-1 hypersecretion in patients with acromegaly and showed a rapid onset of action...
  27. ncbi request reprint Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand
    Song Guang Ren
    Cedars Sinai Research Institute, University of California School of Medicine, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 88:5414-21. 2003
    ..The SRIF/DA chimeric molecule, BIM-23A387, represents a novel tool for effective drug treatment of acromegaly and for prolactinomas otherwise resistant to dopaminergic therapy...
  28. ncbi request reprint Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas
    Anthony P Heaney
    Department of Medicine, Cedars Sinai Research Institute, University of California Los Angeles School of Medicine, Los Angeles, California, USA
    Nat Med 8:1281-7. 2002
    ..Based on these findings, thiazolidinediones may be an effective therapy for Cushing disease..
  29. ncbi request reprint The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion
    Robert D Murray
    Cedars Sinai Research Institute, University of California Los Angeles School of Medicine, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 89:3027-32. 2004
    ..As a consequence of its broader binding profile, SOM230 is likely to find clinical utility in treating tumors resistant to SSTR-2-preferential analogs...
  30. pmc Pituitary senescence: the evolving role of Pttg
    Vera Chesnokova
    Department of Medicine, Division of Endocrinology and Metabolism, Cedars Sinai Medical Center David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA 90048, USA
    Mol Cell Endocrinol 326:55-9. 2010
    ..These observations point to senescence as a target for effective therapy for both tumor silencing and growth restraint towards development of pituitary malignancy...
  31. ncbi request reprint Molecular targets in pituitary tumours
    Anthony P Heaney
    Cedars Sinai Research Institute, 8700 Beverly Blvd, Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA
    Nat Rev Cancer 4:285-95. 2004
  32. doi request reprint The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly
    John D Carmichael
    Department of Medicine, Research Institute, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Room 2015, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 94:523-7. 2009
    ..The OGTT is the gold standard for determining control of GH secretion at diagnosis and after surgical treatment, but the usefulness of performing an OGTT in patients treated with medical therapy has not been determined...
  33. ncbi request reprint Opposing effects of pituitary leukemia inhibitory factor and SOCS-3 on the ACTH axis response to inflammation
    Vera Chesnokova
    Cedars Sinai Research Institute University of California Los Angeles School of Medicine, Los Angeles, California 90048, USA
    Am J Physiol Endocrinol Metab 282:E1110-8. 2002
    ..05). The results indicate that, although LIF induces ACTH, SOCS-3 acts to counterregulate the HPA axis response to inflammation...
  34. ncbi request reprint Current status and future opportunities for controlling acromegaly
    Shlomo Melmed
    Division of Endocrinology and Metabolism, Ceder Sinai Medical Center, Los Angeles, CA 90048, USA
    Pituitary 5:185-96. 2002
    ..Early studies have reported IGF-I normalization in 48% of lanreotide-treated patients and up to 97% of pegvisomant-treated...
  35. pmc In vivo time-lapse imaging delineates the zebrafish pituitary proopiomelanocortin lineage boundary regulated by FGF3 signal
    Ning Ai Liu
    Department of Medicine, Cedars Sinai Research Institute, University of California Los Angeles, Los Angeles, California 90048, USA
    Dev Biol 319:192-200. 2008
    ....
  36. doi request reprint Constitutive activity of somatostatin receptor subtypes
    Anat Ben-Shlomo
    Pituitary Center, Department of Medicine, Cedars Sinai Medical Center, David Geffen School of Medicine atUCLA, Los Angeles, California, USA
    Methods Enzymol 484:149-64. 2010
    ..We describe methodical validation for each of the approaches and the use of a sensitive cAMP assay to analyze consequences of changing membrane receptor number in the absence of an added ligand...
  37. ncbi request reprint Skin manifestations in acromegaly
    Anat Ben-Shlomo
    Department of Medicine, Cedars Sinai Research Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA
    Clin Dermatol 24:256-9. 2006
    ..Discerning these changes contributes to early diagnosis and treatment of this high-morbidity disorder. Controlling GH and IGF-1 over-secretion alleviates most cutaneous manifestations of acromegaly; however, regression may be incomplete...
  38. pmc Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes
    Odelia Cooper
    Pituitary Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Horm Cancer 1:80-92. 2010
    ..As SCAs exhibit features consistent with both corticotroph and gonadotroph cytologic origin, we propose a pathologic and clinically distinct classification of SCAs as silent corticogonadotroph adenomas...
  39. pmc E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumors
    Cuiqi Zhou
    Department of Medicine, Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA
    Mol Endocrinol 23:2000-12. 2009
    ..These results elucidate a mechanism for abundant tumor hPTTG1 expression, whereby Rb inactivation releases E2F1 to induce hPTTG1. This signaling pathway may underlie the requirement of PTTG1 for pituitary tumorigenesis...
  40. ncbi request reprint Implication of pituitary tropic status on tumor development
    Ines Donangelo
    Cedars Sinai Research Institute, UCLA School of Medicine, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Front Horm Res 35:1-8. 2006
    ..Understanding the mechanisms underlying changes in pituitary plasticity and their relationship to tumor development may contribute to the ability of regulating the development and progression of pituitary tumors...
  41. pmc Pituitary tumor transforming gene-null male mice exhibit impaired pancreatic beta cell proliferation and diabetes
    Zhiyong Wang
    Department of Medicine, Cedars Sinai Research Institute, University of California School of Medicine, Los Angeles, CA 90048, USA
    Proc Natl Acad Sci U S A 100:3428-32. 2003
    ..PTTG-/- beta cells had pleiotropic nuclei, suggesting defects in cell division. The results indicated that securin is indispensable for normal pancreatic beta cell proliferation...
  42. ncbi request reprint Discordant proliferation and differentiation in pituitary tumor-transforming gene-null bone marrow stem cells
    Tami Rubinek
    Academic Affairs, Rm 2015, Cedars Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA 90048, USA
    Am J Physiol Cell Physiol 293:C1082-92. 2007
    ..The results indicate that Pttg deletion reduces BMSC proliferation, renders cells more sensitive to hypoxia, and enhances senescent features, thus pointing to a role for Pttg in the maintenance and proliferation of BMSCs...
  43. pmc PPAR-gamma receptor ligands: novel therapy for pituitary adenomas
    Anthony P Heaney
    Cedars Sinai Research Institute, University of California Los Angeles School of Medicine, Los Angeles, California 90048, USA
    J Clin Invest 111:1381-8. 2003
    ..TZDs are proposed as novel oral medications for managing pituitary tumors...
  44. pmc Mechanisms for pituitary tumorigenesis: the plastic pituitary
    Shlomo Melmed
    Cedars Sinai Medical Center, David Geffen School of Medicine, University of California, 8700 Beverly Boulevard, Room 2015, Los Angeles, California 90048, USA
    J Clin Invest 112:1603-18. 2003
    ....
  45. ncbi request reprint Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion
    Song Guang Ren
    Cedars Sinai Research Institute, University of California, Los Angeles, School of Medicine, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 88:4239-45. 2003
    ....
  46. ncbi request reprint Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules
    Anna Gruszka
    Division of Endocrinology, Cedars Sinai Research Institute, University of California School of Medicine, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Endocrinology 148:6107-14. 2007
    ..The results show that SRIF analogs and SRIF/DA molecules inhibit GH and PRL secretion and suppress PRL but not GH gene expression...
  47. pmc Pituitary hypoplasia in Pttg-/- mice is protective for Rb+/- pituitary tumorigenesis
    Vera Chesnokova
    Cedars Sinai Research Institute, David Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA
    Mol Endocrinol 19:2371-9. 2005
    ..01). Pituitary hypoplasia, associated with suppressed cell proliferation, prevents the high penetrance of pituitary tumors in Rb+/- animals, and is therefore a protective determinant for pituitary tumorigenesis...
  48. ncbi request reprint A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly
    Shlomo Melmed
    Department of Medicine, Cedars Sinai Research Institute, David Geffen School of Medicine, University of California, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 90:4405-10. 2005
    ....
  49. ncbi request reprint Minireview: Neuro-immuno-endocrine modulation of the hypothalamic-pituitary-adrenal (HPA) axis by gp130 signaling molecules
    Vera Chesnokova
    Cedars Sinai Research Institute, University of California Los Angeles School of Medicine, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Endocrinology 143:1571-4. 2002
    ..At the same time, gp130 cytokines stimulate pituitary suppressor of cytokine signaling (SOCS)-3, which represses cytokine signaling and abrogates cytokine-induced corticotroph POMC gene transcription and ACTH secretion...
  50. pmc Pituitary somatostatin receptor signaling
    Anat Ben-Shlomo
    Pituitary Center, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Trends Endocrinol Metab 21:123-33. 2010
    ..Elucidating pituitary SRIF receptor signaling enables understanding of pituitary hormone secretion and cell growth, and also encourages future therapeutic development for pituitary disorders...
  51. doi request reprint Update in pituitary disease
    Shlomo Melmed
    Cedars Sinai Medical Center David Geffen UCLA School of Medicine, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 93:331-8. 2008
    ..Notably, they open up new vistas for creative scholarship in unraveling the challenges of pituitary medicine...
  52. pmc Heregulin regulates prolactinoma gene expression
    George Vlotides
    Department of Medicine, Cedars Sinai Medical Center, University of California School of Medicine, Los Angeles, CA, USA
    Cancer Res 69:4209-16. 2009
    ..Targeted inhibition of up-regulated p185(c-neu)/ErbB3 activity could be useful for the treatment of aggressive prolactinomas resistant to conventional therapy...
  53. pmc Oct-1 induces pituitary tumor transforming gene expression in endocrine tumors
    Cuiqi Zhou
    Department of Medicine Pathology, David Geffen School of Medicine at UCLA, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Endocr Relat Cancer 15:817-31. 2008
    ..05) respectively. The results show that Oct-1 transactivates hPTTG1, and both proteins are concordantly overexpressed in endocrine tumors, thus offering a mechanism for endocrine tumor hPTTG1 abundance...
  54. ncbi request reprint Treatment of acromegaly: future
    Ines Donangelo
    Cedars Sinai Research Institute, UCLA David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA
    Endocrine 28:123-8. 2005
    ..Careful individualization of therapy is important in deciding the ideal treatment approach, and primary medical therapy may be recommended in selected patients...
  55. ncbi request reprint Pituitary tumor transforming gene: an update
    Run Yu
    Cedars Sinai Research Institute, UCLA School of Medicine, Los Angeles, CA 90048, USA
    Front Horm Res 32:175-85. 2004
    ....
  56. pmc Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis
    Robert D Murray
    Department of Medicine, Cedars Sinai Research Institute, UCLA School of Medicine, Los Angeles, California 90048, USA
    J Clin Invest 114:349-56. 2004
    ..The results demonstrate that SRIF acts both centrally and peripherally to control the GH-IGF-I axis, providing a mechanistic explanation for SRIF analog action in treating patients with GH-secreting pituitary adenomas...
  57. ncbi request reprint A novel molecular marker of pituitary tumor transforming gene involves in a rat liver regeneration
    Kozo Akino
    Department of Medicine, Cedars Sinai Research Institute UCLA School of Medicine, Los Angeles, California, USA
    J Surg Res 129:142-6. 2005
    ..Because the liver is a regenerative organ, the relevant biological function of PTTG in the liver would be more feasible to understand PTTG. Also, PTTG may be involved in the liver regeneration...
  58. ncbi request reprint Body mass index determines evoked growth hormone (GH) responsiveness in normal healthy male subjects: diagnostic caveat for adult GH deficiency
    Vivien S Bonert
    Department of Medicine, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Room 2015, Los Angeles, CA 90048, USA
    J Clin Endocrinol Metab 89:3397-401. 2004
    ....
  59. ncbi request reprint Pituitary tumor transforming gene overexpression facilitates pituitary tumor development
    Ines Donangelo
    Department of Medicine, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048, USA
    Endocrinology 147:4781-91. 2006
    ....
  60. ncbi request reprint Pituitary corticotroph ontogeny and regulation in transgenic zebrafish
    Ning Ai Liu
    Department of Medicine, Cedars Sinai Research Institute, University of California Los Angeles School of Medicine, 90048, USA
    Mol Endocrinol 17:959-66. 2003
    ..Transgenic zebrafish with specific POMC-GFP expression in pituitary corticotrophs offers a powerful genetic system for in vivo study of vertebrate corticotroph lineage development...
  61. ncbi request reprint Human pituitary tumor-transforming gene (PTTG1) motif suppresses prolactin expression
    Gregory A Horwitz
    Cedars Sinai Medical Center, 8700 Beverly Boulevard, Room 2015, Los Angeles, California 90048, USA
    Mol Endocrinol 17:600-9. 2003
    ..These results indicate that targeting PTTG1-mediated signaling alters the hormonal phenotype in pituitary cells and disrupted PTTG1 action may be a potential subcellular therapeutic tool for repressing PRL hypersecretion...
  62. ncbi request reprint Aryl hydrocarbon receptor interacting protein variants in sporadic pituitary adenomas
    Run Yu
    Cedars Sinai Medical Center, 8700 Beverly Boulevard, Room 2015, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 91:5126-9. 2006
    ....
  63. pmc Functional role of estrogen in pituitary tumor pathogenesis
    Anthony P Heaney
    Cedars Sinai Research Institute, University of California Los Angeles School of Medicine, Los Angeles, California, USA
    J Clin Invest 109:277-83. 2002
    ....
  64. ncbi request reprint Overexpressed pituitary tumor-transforming gene causes aneuploidy in live human cells
    Run Yu
    Cedars Sinai Research Institute, Universityof California Los Angeles School of Medicine, 90048, USA
    Endocrinology 144:4991-8. 2003
    ..These results demonstrate that PTTG induces aneuploidy in single, live, human cancer cells...
  65. pmc Acromegaly pathogenesis and treatment
    Shlomo Melmed
    Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Clin Invest 119:3189-202. 2009
    ..Effective control of GH and IGF1 hypersecretion and ablation or stabilization of the pituitary tumor mass lead to improved comorbidities and lowering of mortality rates for this hormonal disorder...
  66. doi request reprint Pituitary tumour-transforming gene (PTTG) and pituitary senescence
    Vera Chesnokova
    Cedars Sinai Medical Center, David Geffen School of Medicine, Los Angeles, CA 90048, USA
    Horm Res 71:82-7. 2009
    ..These results improve our understanding of pituitary syndromes associated with infertility, growth disorders, hypercortisolism or adrenal, thyroid and gonadal failure due to abrogated pituitary function...
  67. ncbi request reprint Pituitary tumor-transforming gene: physiology and implications for tumorigenesis
    George Vlotides
    Department of Medicine, Cedars Sinai Medical Center, University of California School of Medicine, Los Angeles, California 90048, USA
    Endocr Rev 28:165-86. 2007
    ..Recent knowledge gained from PTTG1-null mouse models and transgenic animals and their potential application to subcellular therapeutic targeting PTTG1 are discussed...
  68. ncbi request reprint Early multipotential pituitary focal hyperplasia in the alpha-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice
    Rula A Abbud
    Department of Medicine, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Mol Endocrinol 19:1383-91. 2005
    ..These results provide evidence for early pituitary plasticity, whereby PTTG overexpression results in a phenotype switch in early pituitary stem cells and promotes differentiated polyhormonal cell focal expansion...
  69. ncbi request reprint Acromegaly with moderate hyperprolactinemia caused by an intrasellar macroadenoma
    Vivien S Bonert
    Cedars Sinai Medical Center, Los Angeles, CA, USA
    Nat Clin Pract Endocrinol Metab 2:408-12; quiz following 412. 2006
    ..After 6 months, however, she complained of persistent frontal headache and a repeat MRI revealed that the adenoma had increased in size to 16 mm. The patient was referred to an endocrinologist for further evaluation...
  70. doi request reprint Pathogenesis of pituitary tumors
    Run Yu
    Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Prog Brain Res 182:207-27. 2010
    ....
  71. pmc Pyridoxal phosphate inhibits pituitary cell proliferation and hormone secretion
    Song Guang Ren
    Department of Medicine, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Room 2015, Los Angeles, California 90048, USA
    Endocrinology 147:3936-42. 2006
    ..Pyridoxine may therefore be appropriate for testing as a relatively safe drug for adjuvant treatment of hormone-secreting pituitary adenomas...
  72. ncbi request reprint Aryl hydrocarbon receptor interacting protein and pituitary tumorigenesis: another interesting protein
    Shlomo Melmed
    J Clin Endocrinol Metab 92:1617-9. 2007
  73. ncbi request reprint The cell adhesion molecules N-cadherin and neural cell adhesion molecule regulate human growth hormone: a novel mechanism for regulating pituitary hormone secretion
    Tami Rubinek
    Institute of Endocrinology, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel
    J Clin Endocrinol Metab 88:3724-30. 2003
    ..05). This study indicates that pituitary cell-cell contact mediated by homophilic interactions between adhesion molecules regulates human GH secretion...
  74. ncbi request reprint Elevated circulating leukemia inhibitory factor in patients with extensive burns
    Sadanori Akita
    Division of Plastic and Reconstructive Surgery, Department of Developmental and Reconstructive Medicine Nagasaki University, Graduate School of Biomedical and Sciences, Nagasaki, Japan
    J Burn Care Res 27:221-5. 2006
    ..30; P < .01) as was the correlation of serum LIF with plasma ACTH (r = .24; P < .01). Serum LIF as well as HPA axis activity markers is a good marker of disease severity and prognosis in patients with extensive burns...
  75. ncbi request reprint Elucidating the murine brain transcriptional network in a segregating mouse population to identify core functional modules for obesity and diabetes
    Pek Yee Lum
    Rosetta Inpharmatics, LLC, Merck and Co, Inc, Seattle, WA 98109, USA
    J Neurochem 97:50-62. 2006
    ..We identify core functional modules making up the brain transcriptional network in mice that are coherent for core biological processes associated with metabolic disease traits including obesity and diabetes...
  76. ncbi request reprint Angiogenesis in endocrine tumors
    Helen E Turner
    Department of Endocrinology, Churchill Hospital, Oxford OX3 7LJ, United Kingdom
    Endocr Rev 24:600-32. 2003
    ..An understanding of the balance of angiogenesis in these vascular tumors and mechanisms of vascular control may assist in therapeutic decisions and allow appropriately targeted treatment...
  77. ncbi request reprint Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm
    David R Clemmons
    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    J Clin Endocrinol Metab 88:4759-67. 2003
    ..Pegvisomant is the most effective drug treatment for acromegaly in normalizing IGF-I and producing a clinical response; it is the preferred agent in patients resistant to or intolerant of somatostatin analogs...
  78. ncbi request reprint Acromegaly consensus: the next steps
    Andrea Giustina
    J Clin Endocrinol Metab 88:1913-4. 2003
  79. ncbi request reprint Prolactin receptor signaling mediates the osmotic response of embryonic zebrafish lactotrophs
    Ning Ai Liu
    Department of Medicine, Cedars Sinai Research Institute, University of California, Los Angeles, California 90048, USA
    Mol Endocrinol 20:871-80. 2006
    ....
  80. ncbi request reprint 2004 World Health Organization classification of pituitary tumors: what is new?
    Shlomo Melmed
    Acta Neuropathol 111:78-9. 2006
  81. ncbi request reprint The neuroprotective WldS gene regulates expression of PTTG1 and erythroid differentiation regulator 1-like gene in mice and human cells
    Thomas H Gillingwater
    Centre for Neuroscience Research, University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, UK
    Hum Mol Genet 15:625-35. 2006
    ..Targeting Wld(S)-induced gene expression may lead to novel therapies for neurodegeneration induced by trauma or by disease in humans...
  82. ncbi request reprint [Pituitary tumorigenesis]
    Marcello D Bronstein
    Departamento de Clinica Medica, Hospital das Clinicas, FMUSP, Sao Paulo, SP
    Arq Bras Endocrinol Metabol 49:615-25. 2005
    ..Several molecular mechanisms involved in pituitary tumorigenesis have been unraveled including oncogenes, tumor suppressor genes and growth factors involved in neoplastic development, and will be described in this review...
  83. ncbi request reprint Supplemental growth hormone in healthy adults: the endocrinologist's responsibility
    Shlomo Melmed
    Nat Clin Pract Endocrinol Metab 2:119. 2006
  84. doi request reprint A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly
    Robert D Murray
    Department of Endocrinology, Leeds Teaching Hospitals National Health Service Trust, Leeds, UK
    J Clin Endocrinol Metab 93:2957-68. 2008
    ..A novel aqueous formulation of lanreotide, lanreotide Autogel (ATG), has recently been approved and is the predominant (and only in the United States) formulation of lanreotide used clinically...
  85. pmc Ovarian hyperstimulation syndrome caused by an FSH-secreting pituitary adenoma
    Odelia Cooper
    Cedars Sinai Medical Center, 8700 Beverly Boulevard, Room 2015, Los Angeles, CA 90048, USA
    Nat Clin Pract Endocrinol Metab 4:234-8. 2008
    ..A 40-year-old woman presented with galactorrhea and oligomenorrhea. She had a history of multiple ovarian cysts and pelvic pain...
  86. ncbi request reprint Expression and function of pituitary tumour transforming gene for T-lymphocyte activation
    Rostyslav Stoika
    Division of Endocrinology, Cedars Sinai Research Institute UCLA School of Medicine, Los Angeles, CA 90048, USA
    Br J Haematol 119:1070-4. 2002
    ..These results showed that PTTG-1 expression follows cell cycling patterns in T lymphocytes, providing a convenient model for studying PTTG functions in normal cells...